{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T21:14:57Z","timestamp":1778793297123,"version":"3.51.4"},"reference-count":22,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2019,3,19]],"date-time":"2019-03-19T00:00:00Z","timestamp":1552953600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"},{"start":{"date-parts":[[2019,5,13]],"date-time":"2019-05-13T00:00:00Z","timestamp":1557705600000},"content-version":"vor","delay-in-days":55,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["UL1TR002529"],"award-info":[{"award-number":["UL1TR002529"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000069","name":"National Institute of Arthritis and Musculoskeletal and Skin Diseases","doi-asserted-by":"publisher","award":["P30AR072581"],"award-info":[{"award-number":["P30AR072581"]}],"id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["asbmr.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2019,8,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:p>In autosomal dominant osteopetrosis type 2 (ADO2) CLCN7 mutations cause impaired osteoclast function. Severe consequences include skeletal fragility despite high bone mass, osteomyelitis, osteonecrosis, bone marrow failure, and severe cranial nerve impingement. There is no effective medical treatment for ADO2. We recruited subjects with ADO2 into a 14-week, open-label, pilot clinical trial of interferon gamma-1b. Doses were titrated based on tolerability and if fasting serum C-telopeptide (CTX) was &amp;lt;25% above baseline at week 8, targeting doses of 100\u2009\u00b5g\/m2 three times a week. The primary outcomes were change from baseline in CTX and N-telopeptide\/creatinine ratio (NTX\/Cr) at week 14. Secondary outcomes included changes in urine calcium\/creatinine ratio, bone formation markers and tolerability. Nine adults and three children were recruited. Severe manifestations of ADO2 included histories of fractures (100%), osteomyelitis (16.7%), vision loss (50%), and anemia (58.3%). Baseline CTX and NTX\/Cr were generally low-normal. Procollagen type I N-terminal propeptide was elevated or in the upper-normal range in 11 of 12 (91.6%) subjects. Elevations of aspartate aminotransferase (AST) and lactate dehydrogenase (LDH) were common. One subject withdrew due to rash. Five subjects achieved doses of 50\u2009\u00b5g\/m2 3 days a week, while six reached the full dose of 100\u2009\u00b5g\/m2 3 days a week. Only 3 of 11 (27.3%) completing subjects achieved the primary outcome of increasing CTX \u226525% above baseline at week 14. The mean \u00b1 SD change from baseline in CTX at week 14 was +2.2% \u00b1 43.2%, p = 0.86). Likewise, there was no significant change in NTX\/Cr (mean change \u20132.1%, p = 0.81). Interferon gamma-1b was poorly tolerated. Most subjects had adverse events, and the Mental Health and Mental Component Scales of the SF-36v2 health survey declined slightly (p &amp;lt; 0.05). Over 14 weeks, interferon gamma-1b failed to significantly increase bone turnover markers in ADO2 and was poorly tolerated. Consequently, interferon gamma-1b is unlikely to be effective for decreasing bone mass in ADO2. \u00a9 2019 American Society for Bone and Mineral Research.<\/jats:p>","DOI":"10.1002\/jbmr.3715","type":"journal-article","created":{"date-parts":[[2019,3,20]],"date-time":"2019-03-20T04:01:09Z","timestamp":1553054469000},"page":"1436-1445","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Interferon Gamma-1b Does Not Increase Markers of Bone Resorption in Autosomal Dominant Osteopetrosis"],"prefix":"10.1093","volume":"34","author":[{"given":"Erik A","family":"Imel","sequence":"first","affiliation":[{"name":"Department of Pediatrics Indiana University School of Medicine Indianapolis IN USA"},{"name":"Department of Medicine Indiana University School of Medicine Indianapolis IN USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ziyue","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Biostatistics Indiana University School of Public Health Indianapolis IN USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dena","family":"Acton","sequence":"additional","affiliation":[{"name":"Department of Medicine Indiana University School of Medicine Indianapolis IN USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melissa","family":"Coffman","sequence":"additional","affiliation":[{"name":"Department of Medicine Indiana University School of Medicine Indianapolis IN USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Netsanet","family":"Gebregziabher","sequence":"additional","affiliation":[{"name":"Department of Biostatistics Indiana University School of Public Health Indianapolis IN USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Tong","sequence":"additional","affiliation":[{"name":"Department of Biostatistics Indiana University School of Public Health Indianapolis IN USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael J","family":"Econs","sequence":"additional","affiliation":[{"name":"Department of Medical and Molecular Genetics Indiana University School of Medicine Indianapolis IN USA"},{"name":"Department of Medicine Indiana University School of Medicine Indianapolis IN USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2019,3,19]]},"reference":[{"issue":"25","key":"2024021014465473700_jbmr3715-bib-0001","doi-asserted-by":"crossref","first-page":"2861","DOI":"10.1093\/hmg\/10.25.2861","article-title":"Albers-Schonberg disease (autosomal dominant osteopetrosis, type II) results from mutations in the ClCN7 chloride channel gene","volume":"10","author":"Cleiren","year":"2001","journal-title":"Hum Mol Genet"},{"issue":"8","key":"2024021014465473700_jbmr3715-bib-0002","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1359\/jbmr.2003.18.8.1513","article-title":"Chloride channel 7 (ClCN7) gene mutations and autosomal dominant osteopetrosis, type II","volume":"18","author":"Waguespack","year":"2003","journal-title":"J Bone Miner Res"},{"key":"2024021014465473700_jbmr3715-bib-0003","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.bone.2013.10.021","article-title":"Generation of the first autosomal dominant osteopetrosis type II (ADO2) disease models","volume":"59","author":"Alam","year":"2014","journal-title":"Bone."},{"issue":"3","key":"2024021014465473700_jbmr3715-bib-0004","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1210\/jc.2006-1986","article-title":"Autosomal dominant osteopetrosis: clinical severity and natural history of 94 subjects with a chloride channel 7 gene mutation","volume":"92","author":"Waguespack","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2024021014465473700_jbmr3715-bib-0005","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S8756-3282(99)00244-6","article-title":"Type II autosomal dominant osteopetrosis (Albers-Schonberg disease): clinical and radiological manifestations in 42 patients","volume":"26","author":"Benichou","year":"2000","journal-title":"Bone."},{"issue":"7","key":"2024021014465473700_jbmr3715-bib-0006","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1359\/jbmr.060409","article-title":"Disease status in autosomal dominant osteopetrosis type 2 is determined by osteoclastic properties","volume":"21","author":"Chu","year":"2006","journal-title":"J Bone Miner Res"},{"issue":"7","key":"2024021014465473700_jbmr3715-bib-0007","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1056\/NEJM198402163100701","article-title":"Treatment of congenital osteopetrosis with high-dose calcitriol","volume":"310","author":"Key","year":"1984","journal-title":"N Engl J Med"},{"issue":"2","key":"2024021014465473700_jbmr3715-bib-0008","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/S0022-3476(05)81700-7","article-title":"Malignant osteopetrosis treated with high doses of 1 alpha-hydroxyvitamin D3 and interferon gamma","volume":"123","author":"Kubo","year":"1993","journal-title":"J Pediatr."},{"issue":"10","key":"2024021014465473700_jbmr3715-bib-0009","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1007\/BF02073378","article-title":"Failure of calcitriol treatment in a patient with malignant osteopetrosis","volume":"152","author":"van Lie Peters","year":"1993","journal-title":"Eur J Pediatr"},{"issue":"1","key":"2024021014465473700_jbmr3715-bib-0010","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0022-3476(05)82557-0","article-title":"Recombinant human interferon gamma therapy for osteopetrosis","volume":"121","author":"Key","year":"1992","journal-title":"J Pediatr."},{"issue":"24","key":"2024021014465473700_jbmr3715-bib-0011","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1056\/NEJM199506153322402","article-title":"Long-term treatment of osteopetrosis with recombinant human interferon gamma","volume":"332","author":"Key","year":"1995","journal-title":"N Engl J Med"},{"key":"2024021014465473700_jbmr3715-bib-0012","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.bone.2016.10.016","article-title":"Phenotypic severity of autosomal dominant osteopetrosis type II (ADO2) mice on different genetic backgrounds recapitulates the features of human disease","volume":"94","author":"Alam","year":"2017","journal-title":"Bone."},{"issue":"11","key":"2024021014465473700_jbmr3715-bib-0013","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1002\/jbmr.2545","article-title":"Interferon gamma, but not calcitriol improves the osteopetrotic phenotypes in ADO2 mice","volume":"30","author":"Alam","year":"2015","journal-title":"J Bone Miner Res"},{"issue":"6","key":"2024021014465473700_jbmr3715-bib-0014","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1185\/03007995.2014.899209","article-title":"A short 2 week dose titration regimen reduces the severity of flu-like symptoms with initial interferon gamma-1b treatment","volume":"30","author":"Devane","year":"2014","journal-title":"Curr Med Res Opin"},{"key":"2024021014465473700_jbmr3715-bib-0015","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1097\/00003086-199309000-00010","article-title":"Osteopetrosis. The pharmaco-physiologic basis of therapy","volume":"294","author":"Key","year":"1993","journal-title":"Clin Orthop Relat Res"},{"issue":"5","key":"2024021014465473700_jbmr3715-bib-0016","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1210\/jcem.87.5.8497","article-title":"Measurement of tartrate-resistant acid phosphatase and the brain isoenzyme of creatine kinase accurately diagnoses type II autosomal dominant osteopetrosis but does not identify gene carriers","volume":"87","author":"Waguespack","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"2024021014465473700_jbmr3715-bib-0017","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1002\/jbmr.130","article-title":"Elevated serum lactate dehydrogenase isoenzymes and aspartate transaminase distinguish Albers-Schonberg disease (Chloride Channel 7 Deficiency Osteopetrosis) among the sclerosing bone disorders","volume":"25","author":"Whyte","year":"2010","journal-title":"J Bone Miner Res"},{"issue":"2","key":"2024021014465473700_jbmr3715-bib-0018","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.bone.2008.08.130","article-title":"Bone density, strength, and formation in adult cathepsin K (-\/-) mice","volume":"44","author":"Pennypacker","year":"2009","journal-title":"Bone."},{"key":"2024021014465473700_jbmr3715-bib-0019","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.bone.2016.04.024","article-title":"Effects of long term treatment with high doses of odanacatib on bone mass, bone strength, and remodeling\/modeling in newly ovariectomized monkeys","volume":"88","author":"Duong","year":"2016","journal-title":"Bone."},{"issue":"3","key":"2024021014465473700_jbmr3715-bib-0020","first-page":"193","article-title":"Elevated serum 1,25-dihydroxyvitamin D in osteopetrotic mutations in three species","volume":"2","author":"Zerwekh","year":"1987","journal-title":"Bone Miner."},{"issue":"3","key":"2024021014465473700_jbmr3715-bib-0021","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1385\/ENDO:11:3:309","article-title":"Skeletal resistance to 1,25-dihydroxyvitamin D3 in osteopetrotic rats","volume":"11","author":"Safadi","year":"1999","journal-title":"Endocrine."},{"issue":"1","key":"2024021014465473700_jbmr3715-bib-0022","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1002\/jbmr.5650040109","article-title":"Treatment of congenital osteopetrosis in the rabbit with high-dose 1,25-dihydroxyvitamin D","volume":"4","author":"Popoff","year":"1989","journal-title":"J Bone Miner Res"}],"container-title":["Journal of Bone and Mineral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jbmr.3715","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/jbmr.3715","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/34\/8\/1436\/56654680\/jbmr3715.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/34\/8\/1436\/56654680\/jbmr3715.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T15:03:45Z","timestamp":1710342225000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jbmr\/article\/34\/8\/1436-1445\/7605873"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,19]]},"references-count":22,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2019,3,19]]},"published-print":{"date-parts":[[2019,8,1]]}},"URL":"https:\/\/doi.org\/10.1002\/jbmr.3715","relation":{},"ISSN":["0884-0431","1523-4681"],"issn-type":[{"value":"0884-0431","type":"print"},{"value":"1523-4681","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,8,1]]},"published":{"date-parts":[[2019,3,19]]},"assertion":[{"value":"2018-11-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-03-10","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-05-13","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}